Stockscreener 앱 받기
46.18
0.67%
-0.31
시간 외 거래:
46.00
-0.18
-0.39%
Tempus Ai Inc 주식(TEM)의 최신 뉴스
Tempus AI, Inc. (TEM) and Bristol Myers Announce a Strategic Partnership - Insider Monkey
Tempus AI, Inc. Class A Common Stock (TEM) Live Share Price, Invest From India - INDmoney
Tempus AI (NASDAQ: TEM) investors choose 3-year say-on-pay cycle - Stock Titan
Tempus AI Stock (TEM) Opinions on Fund Holdings and Trading Strategies - Quiver Quantitative
Tempus AI: Taking Advantage Of Investor Myopia (NASDAQ:TEM) - Seeking Alpha
Tempus releases digital test for prostate cancer prognosis - Crain's Chicago Business
Tempus AI Insiders Sold Shares Worth Over $1.5M - TradingView
Tempus AI (TEM) Diagnostics CEO sells 1,580 shares for RSU tax withholding - Stock Titan
Tempus AI (TEM) CFO’s mandated share sale covers RSU tax obligations - Stock Titan
Tempus AI (TEM) legal chief’s non-discretionary tax sell-to-cover trade - Stock Titan
Tempus AI (TEM) CEO Lefkofsky sells 22,335 shares to cover RSU taxes - Stock Titan
Tempus AI (TEM) executive logs 13,550-share tax sell-to-cover transaction - Stock Titan
Tempus AI (TEM) CAO executes mandatory sell-to-cover for RSU taxes - Stock Titan
Tempus AI Launches AI Powered Prostate Cancer Risk Test - Moomoo
Tempus launches AI prostate cancer test on its platform - Investing.com UK
Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients - Stocktwits
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use - Yahoo Finance
1TEM.MI Stock Price, Quote & Chart | TEMPUS AI INC-CL A (BIT:1TEM) - ChartMill
TEM (NASDAQ: TEM) director reports sale of 2,902 shares for $171K - Stock Titan
James W. Rogers sells 21,498 shares at TEM (NASDAQ: TEM) - Stock Titan
[144] Tempus AI, Inc. SEC Filing - Stock Titan
TEM (NASDAQ: TEM) notice: insider plans to sell RSU-derived Class A shares - Stock Titan
TEM (NASDAQ: TEM) Rule 144 lists RSUs and two 10b5-1 sales by Andrew Polovin - Stock Titan
Eric Lefkofsky sells TEM (NASDAQ: TEM) Class A shares reported in Form 144 - Stock Titan
TEM (NASDAQ: TEM) affiliate seeks to sell 9,592 Class A shares for $566K - Stock Titan
Long term debt to total assets ratio of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery - Benzinga
ETFs Investing in Tempus AI, Inc. Class A Stocks - TradingView
Price to sales ratio of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Cash per share of Tempus AI, Inc. Class A – HAM:F3M - TradingView
Tempus AI, Inc. Class A Trade Ideas — HAM:F3M - TradingView
InvestingPro spotted Tempus AI’s 40% decline months in advance By Investing.com - Investing.com
Tempus AI Earnings Call Highlights Data-Driven Growth - TipRanks
TEM Technical Analysis | Trend, Signals & Chart Patterns | TEMPUS AI INC-CL A (NASDAQ:TEM) - ChartMill
4 Heavily Shorted AI Stocks to Watch Right Now - Schaeffer's Investment Research
Piper Sandler Maintains Tempus AI (TEM) Neutral Recommendation - MSN
US88023BAG8 Bond Analysis — Key Metrics - TradingView
AI in cardiology set to grow as Tempus projects $1.59B 2026 sales - Stock Titan
Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness - Yahoo Finance
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Yahoo Finance
ARK Invest Increases AI and Genomic Holdings While Reducing Semi - GuruFocus
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist - Yahoo Finance
How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here - Barchart.com
7 Healthcare AI Stocks Under $50 With Huge Upside Potential - 24/7 Wall St.
Cathie Wood’s weekly update: buys Cerebras, Tempus AI, sells AMD and TSM (ARKK:BATS) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Tempus AI stock gains following the ALERT trial result announcement - MSN
Tempus AI stock jumps, ALERT trial results boost EHR automation buzz - MSN
Tempus AI shares gain after expanded partnership with Gilead - MSN
Cathie Wood buys $14.9 million of Tempus AI stock - MSN
Tempus AI Inc (TEM) Stock Price, Quote, News & History - Benzinga
Tempus AI (TEM) executive Fukushima Ryan makes bona fide stock gifts under lock-up - Stock Titan
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell? - TradingView
Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Alzheimer’s Blood-Based Biomarker Testing Integrated into Clinical Workflows - Clinical Lab Products
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience - Quantisnow
Tempus AI Stock (TEM) Opinions on Bristol Myers Squibb Partnership Expansion - Quiver Quantitative
Here’s Why Aristotle Core Equity Fund Bets on Tempus AI (TEM), a Healthcare Technology Company - Insider Monkey
Tempus Expands Strategic Collaboration with Bristol Myers Squibb - The National Law Review
FinancialContentTempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience - FinancialContent
Baillie Gifford Reduces Stake in Tempus AI Inc: A Strategic Port - GuruFocus
1.94%
자본화:
|
볼륨(24시간):